| Autor: |
Grace Xiuqing Li, Lan Wang, Bassam Yaghmour, Giridharan Ramsingh, George Yaghmour |
| Jazyk: |
angličtina |
| Rok vydání: |
2018 |
| Předmět: |
|
| Zdroj: |
Leukemia Research Reports, Vol 10, Iss , Pp 26-36 (2018) |
| Druh dokumentu: |
article |
| ISSN: |
2213-0489 |
| DOI: |
10.1016/j.lrr.2018.06.003 |
| Popis: |
Activating mutations in FLT3 in acute myeloid leukemia (AML) portend a poor prognosis, and targeting FLT3 with a tyrosine kinase inhibitor has been an area of intense research recently. Most FLT3 mutated AML patients undergo hematopoietic stem cell transplantation (HSCT) as standard of care but a significant proportion of patients relapse. Although the use of FLT3 inhibitors in the pre-HSCT perspective is more clearly defined, its use in the post-HSCT scenario, when most relapses occur, remains unclear. In this review, we comprehensively present the data on the recent and ongoing studies evaluating the role of various FLT3 inhibitors in AML with a particular focus in the post-HSCT setting. Keywords: Acute myeloid leukemia, FLT3, Hematopoietic stem cell transplant, Tyrosine kinase inhibitors, Multikinase inhibitors, Drug resistance |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
